Retrospective analysis shows improved overall survival and reduced non-relapse mortality with PTCY versus antithymocyte globulin in HLA-mismatched transplants.
Key Points
Improved overall survival with post-transplant cyclophosphamide, achieving 78.7% compared to 56.5% with high-dose ATG.
One-year non-relapse mortality was significantly lower at 7.7% in the PTCY group versus 24.4% in high-dose ATG.
Analysis involved 155 HLA-mismatched unrelated donor stem cell transplantation recipients, highlighting the effectiveness of PTCY.
Post-transplant cyclophosphamide may help reduce graft-versus-host disease mortality while providing similar infection rates.